Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase. A multikinase screen determined that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concentratio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hexner, Elizabeth O., Serdikoff, Cynthia, Jan, Mahfuza, Swider, Cezary R., Robinson, Candy, Yang, Shi, Angeles, Thelma, Emerson, Stephen G., Carroll, Martin, Ruggeri, Bruce, Dobrzanski, Pawel
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2424161/
https://ncbi.nlm.nih.gov/pubmed/17984313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-083402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados